New Heart Stent Cuts Death Rates in Half

Saturday, 09 Mar 2013 10:08 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Stentys said on Saturday that a study has shown its self-expanding stents for keeping blood vessels open have lower mortality rates than other conventional devices.

The French medical technology firm said the study paves the way to new markets for its tiny mesh tubes - which unlike conventional stents fit into the contours of blood vessels, change shape and adapt their diameters as vessels dilate and initial clots dissolve.

"The next step is to open other markets in Europe and in the Middle East, Latin America and maybe Asia," Chief Executive Gonzague Issenmann told Reuters.

SPECIAL:
These 4 Things Happen Right Before a Heart Attack — Read More.

Stentys said it also aims to break into the $3 billion U.S. market, the world's largest for stents.

Data from a study of 1,000 heart patients showed the Stentys device had lower rates of major cardiac events, including death, than conventional stents, Stentys said.

These rates were 9.3 percent for self-expanding stents compared with 11.1 percent for conventional stents, according to the study presented at the American College of Cardiology congress in San Francisco.

Average cardiac death rates were 2 percent compared with rates of 3.9 percent for conventional stents from other published studies.

Stentys is starting a new clinical trial in the United States in the next few weeks with the aim of getting U.S. Food and Drug Administration (FDA) approval as early as 2015.

The company would seek a partner to market the device in the United States if it gets approval, Issenmann said.

It already sells its devices in several European countries including France, Germany, Switzerland, the Netherlands, Italy and Spain.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

2-in-1 Diabetes Pill OKd by FDA

Thursday, 30 Oct 2014 08:19 AM

A new two-in-one diabetes pill from AstraZeneca has been approved by U.S. regulators, the British drugmaker said on Thur . . .

Young People More Likely to Survive Ebola: Study

Thursday, 30 Oct 2014 08:14 AM

Who survives Ebola and why? Health workers treating patients in Sierra Leone, including some who died doing that work, h . . .

Music Program Helps Dementia Patients

Thursday, 30 Oct 2014 08:07 AM

Mike Knutson taught himself to play the harmonica as a child, and the 96-year-old sang with his family for most of his l . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved